Inclusion Criteria:

          -  Measurable locally advanced, recurrent, or metastatic biliary tract carcinoma
             (including intrahepatic or extrahepatic cholangiocarcinoma, gallbladder cancer, or
             ampullary carcinoma).

          -  Patients with locally advanced disease should be unresectable by conventional surgical
             approaches.

          -  Patients with distant metastatic spread must be refractory to approved standard
             systemic therapies (such as gemcitabine, cisplatin, or equivalents) if they are
             eligible to receive these treatments.

          -  Patients must be co-enrolled on the companion protocol HCC 17-220 (Cell Harvest and
             Preparation to Support Adoptive Cell Therapy Clinical Protocols and Pre-Clinical
             Studies) and have available TIL cultures for therapy.

          -  Patients with 3 or fewer brain metastases that are less than 1 cm in diameter and
             asymptomatic are eligible. Lesions that have been treated with stereotactic
             radiosurgery must be clinically stable for 1 month after treatment for the patient to
             be eligible. Patients with surgically resected brain metastases are eligible.

          -  Greater than or equal to 18 years of age and less than or equal to age 75

          -  Able to understand and sign the Informed Consent Document

          -  Clinical performance status of ECOG 0 or 1

          -  Life expectancy of greater than three months

          -  Patients of both genders who are of child-bearing potential must be willing to
             practice birth control from the time of enrollment on this study and for up to four
             months after receiving the treatment.

          -  Serology:

               -  Seronegative for HIV antibody. (The experimental treatment being evaluated in
                  this protocol depends on an intact immune system. Patients who are HIV
                  seropositive can have decreased immune-competence and thus be less responsive to
                  the experimental treatment and more susceptible to its toxicities.)

               -  Seronegative for hepatitis B antigen, and seronegative for hepatitis C antibody.
                  If hepatitis C antibody test is positive, then patient must be tested for the
                  presence of antigen by RT-PCR and be HCV RNA negative.

          -  Women of child-bearing potential must have a negative pregnancy test because of the
             potentially dangerous effects of the treatment on the fetus.

          -  Hematology

               -  Absolute neutrophil count greater than 1000/mm3 without the support of filgrastim

               -  WBC ≥ 3000/mm3

               -  Platelet count ≥ 100,000/mm3

               -  Hemoglobin > 8.0 g/dl

          -  Chemistry

               -  Serum ALT/AST ≤ to 3.5 times the upper limit of normal

               -  Serum creatinine ≤ to 1.6 mg/dl

               -  Total bilirubin ≤ to 2.0 mg/dl, except in patients with Gilbert's Syndrome who
                  must have a total bilirubin less than 3.0 mg/dl.

          -  More than four weeks must have elapsed since any prior systemic therapy at the time
             the patient receives the preparative regimen, and patients' toxicities must have
             recovered to a clinically manageable level (except for toxicities such as alopecia or
             vitiligo). (Note: Patients may have undergone minor surgical procedures within the
             past 3 weeks, as long as all toxicities have recovered to grade 1 or less)

        Exclusion Criteria:

          -  Women of child-bearing potential who are pregnant or breastfeeding because of the
             potentially dangerous effects of the treatment on the fetus or infant.

          -  Any form of primary immunodeficiency (such as Severe Combined Immunodeficiency
             Disease).

          -  Concurrent opportunistic infections (The experimental treatment being evaluated in
             this protocol depends on an intact immune system. Patients who have decreased immune
             competence may be less responsive to the experimental treatment and more susceptible
             to its toxicities).

          -  Active systemic infections (e.g.: requiring anti-infective treatment), coagulation
             disorders or any other active major medical illnesses.

          -  History of clinically significant major organ autoimmune disease

          -  Concurrent systemic steroid therapy.

          -  History of severe immediate hypersensitivity reaction to any of the agents used in
             this study.

          -  History of active coronary or ischemic symptoms.

          -  Documented LVEF of less than or equal to 45%; note: testing is required in patients
             with:

               -  Age > 65 years' old

               -  Clinically significant atrial and or ventricular arrhythmias including but not
                  limited to: atrial fibrillation, ventricular tachycardia, second or third degree
                  heart block or have a history of ischemic heart disease, chest pain.

          -  Documented FEV1 less than or equal to 60% predicted tested in patients with:

               -  A prolonged history of cigarette smoking (20 pk/year of smoking within the past 2
                  years).

               -  Symptoms of respiratory dysfunction

          -  Patients who are receiving any other investigational agents.